




SeraNovo

SERANOVO'S FORMULATION OUTPERFORMS
THE MARKETED ITRACONAZOLE PRODUCT
SPORANOX®

ITRACONAZOLE



Molecular weight 705.6 g/mol

Ionisation Weak base, pKa 2.0 and 3.7

LogP 6.2

Melting point 167 °C

Solvent	Itraconazole solubility (mg/ml)
Water	0.000004
0.1 M HCl	0.005
Propylene glycol	0.2
Tween 20	1.2
PEG400	2.1

SPORANOX® ORAL SOLUTION

Itraconazole concentration 10 mg/ml

Functional excipient

hydroxypropyl-β-cyclodextrin,
400 mg/ml



SERANOVO FORMULATION



Itraconazole concentration 25 mg/ml

Excipients All FDA GRAS status

Presentation Liquid-filled capsule

ORAL BIOAVAILABILITY STUDY

STUDY DESIGN

Dose 5 mg/kg

Administration route Oral

Dosage forms administered in a parallel study


Sporanox®: Oral solution

SeraNovo: Hard gelatin capsule

Animal model Male Sprague-Dawley rats

Nutritional state Fasted

RESULTS



Itraconazole plasma concentration vs time profiles (mean ± standard deviation, n=3)

CONCLUSION

SeraNovo's deep eutectic solvent based formulation exhibited 2,3-fold higher oral bioavailability than the marketed product SporanoX®.